SLC5A2 and type 2 diabetes mellitus: While it is difficult to extrapolate these results and apply them to the non‐diabetic CKD setting, our current study suggest that SGLT2/1 inhibition may provide additional renoprotection, especially when diabetic ketoacidosis is not a concern (Bhatt et al., 2021).